ERBB2 and breast cancer: The treatment of HER2 (+) BC cells with acquired resistance to lapatinib (a tyrosine kinase inhibitor), using a combination of lapatinib and 17-DMAG suppressed the growth of BC cells in vivo and in vitro [136] (Table 1).